Post by Evotec

𝗪𝗲 𝗮𝗿𝗲 𝗽𝗹𝗲𝗮𝘀𝗲𝗱 𝘁𝗼 𝘀𝗵𝗮𝗿𝗲 𝗼𝘂𝗿 𝗹𝗮𝘁𝗲𝘀𝘁 𝗽𝘂𝗯𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻 𝗶𝗻𝘃𝗲𝘀𝘁𝗶𝗴𝗮𝘁𝗶𝗻𝗴 𝗻𝗼𝘃𝗲𝗹 𝘀𝘁𝗿𝗮𝘁𝗲𝗴𝗶𝗲𝘀 𝘁𝗼 𝗲𝗻𝗵𝗮𝗻𝗰𝗲 𝘁𝗵𝗲 𝘁𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰 𝗽𝗼𝘁𝗲𝗻𝘁𝗶𝗮𝗹 𝗼𝗳 𝗧 𝗰𝗲𝗹𝗹 𝗲𝗻𝗴𝗮𝗴𝗲𝗿𝘀 (𝗧𝗖𝗘𝘀) 𝗶𝗻 𝘀𝗼𝗹𝗶𝗱 𝘁𝘂𝗺𝗼𝗿𝘀: https://okt.to/4KeR7q In this study, Evotec scientists, led by Welbeck Danquah, explored a first-in-class preclinical strategy combining a TCE with a separate CD2-targeted bispecific antibody to provide on-tumor T cell costimulation. This combination approach could offer greater dosing flexibility and allow for an improved therapeutic index for TCEs in solid tumors. Key findings about our CD2 bispecific: 🔹Maintains activity even after loss of CD58 by tumor cells – a well-documented mechanism of TCE treatment resistance 🔹Effectively engages CD28-negative CD8 T cells, a large T cell population in elderly patients 🔹Induces markedly lower cytokine release than CD28-based costimulation approaches, supporting a potentially improved safety profile The work is based on a novel proprietary CD2 binder developed at Evotec that targets a unique epitope. A huge thank you to all co-authors and collaborators who contributed to this research.